{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Carlson AL"],"funding":["NIDDK NIH HHS"],"pagination":["178-189"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8971997"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(3)"],"pubmed_abstract":["<b><i>Introduction:</i></b> This trial assessed safety and effectiveness of an advanced hybrid closed-loop (AHCL) system with automated basal (Auto Basal) and automated bolus correction (Auto Correction) in adolescents and adults with type 1 diabetes (T1D). <b><i>Materials and Methods:</i></b> This multicenter single-arm study involved an intent-to-treat population of 157 individuals (39 adolescents aged 14-21 years and 118 adults aged ≥22-75 years) with T1D. Study participants used the MiniMed™ AHCL system during a baseline run-in period in which sensor-augmented pump +/- predictive low glucose management or Auto Basal was enabled for ∼14 days. Thereafter, Auto Basal and Auto Correction were enabled for a study phase (∼90 days), with glucose target set to 100 or 120 mg/dL for ∼45 days, fo"],"journal":["Diabetes technology & therapeutics"],"pubmed_title":["Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes."],"pmcid":["PMC8971997"],"funding_grant_id":["P30 DK045735","P30 DK020572","P30 DK111022"],"pubmed_authors":["Kipnes MS","Shin J","Vella M","Slover RH","Sherr JL","Christiansen M","Grosman B","Lilenquist DR","Thrasher JR","Cordero TL","Jonkers RAM","Rhinehart AS","Chen X","Kaiserman KB","Vigersky RA","Shulman DI","Carlson AL","Pop-Busui R","Roy A","Bode BW","Lee SW","Reed JHC","Brazg RL","Philis-Tsimikas A","Garg SK"],"additional_accession":[]},"is_claimable":false,"name":"Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.","description":"<b><i>Introduction:</i></b> This trial assessed safety and effectiveness of an advanced hybrid closed-loop (AHCL) system with automated basal (Auto Basal) and automated bolus correction (Auto Correction) in adolescents and adults with type 1 diabetes (T1D). <b><i>Materials and Methods:</i></b> This multicenter single-arm study involved an intent-to-treat population of 157 individuals (39 adolescents aged 14-21 years and 118 adults aged ≥22-75 years) with T1D. Study participants used the MiniMed™ AHCL system during a baseline run-in period in which sensor-augmented pump +/- predictive low glucose management or Auto Basal was enabled for ∼14 days. Thereafter, Auto Basal and Auto Correction were enabled for a study phase (∼90 days), with glucose target set to 100 or 120 mg/dL for ∼45 days, fo","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T12:45:21.389Z","creation":"2025-04-04T12:45:21.389Z"},"accession":"S-EPMC8971997","cross_references":{"pubmed":["34694909"],"doi":["10.1089/dia.2021.0319"]}}